Ashique Sumel, Garg Ashish, Hussain Afzal, Farid Arshad, Kumar Prashant, Taghizadeh-Hesary Farzad
Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, India.
Guru Ramdas Khalsa Institute of Science and Technology, Pharmacy, Jabalpur, India.
Cancer Med. 2023 Sep;12(18):18797-18825. doi: 10.1002/cam4.6502. Epub 2023 Sep 5.
BACKGROUND: Cancer treatment is still a global health challenge. Nowadays, chemotherapy is widely applied for treating cancer and reducing its burden. However, its application might be in accordance with various adverse effects by exposing the healthy tissues and multidrug resistance (MDR), leading to disease relapse or metastasis. In addition, due to tumor heterogeneity and the varied pharmacokinetic features of prescribed drugs, combination therapy has only shown modestly improved results in MDR malignancies. Nanotechnology has been explored as a potential tool for cancer treatment, due to the efficiency of nanoparticles to function as a vehicle for drug delivery. METHODS: With this viewpoint, functionalized nanosystems have been investigated as a potential strategy to overcome drug resistance. RESULTS: This approach aims to improve the efficacy of anticancer medicines while decreasing their associated side effects through a range of mechanisms, such as bypassing drug efflux, controlling drug release, and disrupting metabolism. This review discusses the MDR mechanisms contributing to therapeutic failure, the most cutting-edge approaches used in nanomedicine to create and assess nanocarriers, and designed nanomedicine to counteract MDR with emphasis on recent developments, their potential, and limitations. CONCLUSIONS: Studies have shown that nanoparticle-mediated drug delivery confers distinct benefits over traditional pharmaceuticals, including improved biocompatibility, stability, permeability, retention effect, and targeting capabilities.
背景:癌症治疗仍是一项全球性的健康挑战。如今,化疗被广泛应用于治疗癌症并减轻其负担。然而,其应用可能会因暴露健康组织和产生多药耐药性(MDR)而带来各种不良反应,导致疾病复发或转移。此外,由于肿瘤异质性和所开药物不同的药代动力学特征,联合疗法在MDR恶性肿瘤中的疗效仅略有改善。由于纳米颗粒作为药物递送载体的有效性,纳米技术已被探索为一种潜在的癌症治疗工具。 方法:基于这一观点,已对功能化纳米系统作为克服耐药性的潜在策略进行了研究。 结果:该方法旨在通过一系列机制提高抗癌药物的疗效,同时减少其相关副作用,如绕过药物外排、控制药物释放和扰乱代谢。本综述讨论了导致治疗失败的MDR机制、纳米医学中用于创建和评估纳米载体的最前沿方法,以及设计用于对抗MDR的纳米医学,重点是近期进展、其潜力和局限性。 结论:研究表明,纳米颗粒介导的药物递送比传统药物具有明显优势,包括改善生物相容性、稳定性、渗透性、滞留效应和靶向能力。
J Nanobiotechnology. 2022-9-24
Small Methods. 2024-1
Adv Drug Deliv Rev. 2013-7-21
Drug Resist Updat. 2021-9
Mini Rev Med Chem. 2017
Drug Resist Updat. 2020-5
Drug Resist Updat. 2017-5-21
Drug Resist Updat. 2021-3
Cancer Drug Resist. 2024-6-21
J Cancer Res Clin Oncol. 2023-8
Genes (Basel). 2022-9-26
Int J Mol Sci. 2022-6-15
Cancers (Basel). 2022-5-13
Cancer Drug Resist. 2020-10-12
Cancer Drug Resist. 2021-6-19
Front Pharmacol. 2022-1-10